Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1

Matrix Biology

Volumn 26, Issue 4, 2007, Pages 269-279

  Ghose Roy, Sreerupa ^a   Mishra, Sumita ^a   Ghosh, Goutam ^a   Bandyopadhyay, Arun ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Collagen; Extracellular matrix; Fibrosis; Heart; Matrix Metalloproteinase; Thyroid hormone

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DEXAMETHASONE; GLUCOCORTICOID; INTERSTITIAL COLLAGENASE; LIOTHYRONINE; MESSENGER RNA; PROCOLLAGEN; THYROID HORMONE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTHYROIDISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RAT; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; COLLAGEN; DEXAMETHASONE; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; MALE; MATRIX METALLOPROTEINASE 1; MUSCLE CONTRACTION; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; THYROID HORMONES; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; TRIIODOTHYRONINE;

ANIMALIA; RATTUS;

EID: 34247579732     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2006.12.005     Document Type: Article

References (48)

1. Bandyopadhyay A., Shin D.W., Ahn J.O., and Kim D.H. Calcineurin regulates ryanodine receptor/Ca(2+)-release channels in rat heart. Biochem. J. 352 (2000) 61-70
2. Bernal-Mizrachi C., Weng S., Feng C., Finck B.N., Knutsen R.H., Leone T.C., Coleman T., Mecham R.P., Kelly D.P., and Semenkovich C.F. Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor-null mice. Nat. Med. 9 (2003) 1069-1075
3. Brilla C.G., Matsubara L., and Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 28 (1996) 269-275
4. Chen W.J., Lin K.H., and Lee Y.S. Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-alpha1(I) collagen gene expression by thyroid hormone receptor. Mol. Cell. Endocrinol. 162 (2000) 45-55
5. Chen H., Li D., Saldeen T., and Mehta J.L. TGF-β1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H1612-H1617
6. Chien K.R., Zhu H., Knowlton K.U., Miller-Hance W., van-Bilsen M., O'Brien T.X., and Evans S.M. Transcriptional regulation during cardiac growth and development. Annu. Rev. Physiol. 55 (1993) 77-95
7. Creemers E.E., Cleutjens J.P., Smits J.F., and Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ. Res. 89 (2001) 201-210
8. De K., Ghosh G., Datta M., Konar A., Bandyopadhyay J., Bandyopadhyay D., Bhattacharya S., and Bandyopadhyay A. Analysis of differentially expressed genes in hyperthyroid-induced hypertrophied heart by cDNA microarray. J. Endocrinol. 182 (2004) 303-314
9. Degens H., Gilde A.J., Lindhout M., Willemsen P.H., Van Der Vusse G.J., and Van Bilsen M. Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H108-H115
10. Diez J., Querejeta R., Lopez B., Gonzalez A., Larman M., and Martinez Ubago J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002) 2512-2517
11. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77 (1995) 863-868
12. Fadel B.M., Ellahham S., Ringel M.D., Lindsay Jr. J., Wartofsky L., and Burman K.D. Hyperthyroid heart disease. Clin. Cardiol. 23 (2000) 402-408
13. Fedak P.W., Altamentova S.M., Weisel R.D., Nili N., Ohno N., Verma S., Lee T.Y., Kiani C., Mickle D.A., Strauss B.H., and Li R.K. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H626-H634
14. Fedak P.W., Smookler D.S., Kassiri Z., Ohno N., Leco K.J., Verma S., Mickle D.A., Watson K.L., Hojilla C.V., Cruz W., Weisel R.D., Li R.K., and Khokha R. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110 (2004) 2401-2409
15. Feldman A.M., Weinberg E.O., Ray P.E., and Lorell B.H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ. Res. 73 (1993) 184-192
16. Fujisawa G., Okada K., Muto S., Fujita N., Itabashi N., Kusano E., and Ishibashi S. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac. Hypertension 41 (2003) 493-498
17. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., Amento E., and Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 75 (1994) 181-189
18. Gelse K., Poschl E., and Aigner T. Collagens-structure, function, and biosynthesis. Adv. Drug Deliv. Rev. 55 (2003) 1531-1546
19. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74 (1997) 111-122
20. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., and Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem. 271 (1996) 30375-30380
21. Grunfeld J.P., and Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension 10 (1987) 608-618
22. Hamasaki Y., Shinohara O., Ishida H., Hayashi Y., and Nakazawa H. Decreased protein kinase C-epsilon expression in hypertrophied cardiac ventricles induced by triiodothyronine treatment in the rat. Life Sci. 67 (2000) 1859-1868
23. Iimoto D.S., Covell J.W., and Harper E. Increase in cross-linking of type I and type III collagens associated with volume-overload hypertrophy. Circ. Res. 63 (1988) 399-408
24. Illman S.A., Keski-oja J., Parks W.C., and Lohi J. The mouse matrix metalloproteinase, epilysin (MMP-28), is alternatively spliced and processed by a furin-like proprotein convertase. Biochem. J. 375 (2003) 191-197
25. Klein I., and Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344 (2001) 501-509
26. Kossakowska A.E., Edwards D.R., Lee S.S., Urbanski L.S., Stabbler A.L., Zhang C.L., Philips B.W., Zhang Y., and Urbanski S.J. Altered balance between matrix metalloproteainases and their inhibitors in experimental biliary fibrosis. Am. J. Pathol. 153 (1998) 1895-1902
27. Leco K.J., Khokha R., Pavloff N., Hawkes S.P., and Edwards D.R. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. 269 (1994) 9352-9360
28. Lovelock J.D., Baker A.H., Gao F., Dong J.F., Bergeron A.L., McPheat W., Sivasubramanian N., and Mann D.L. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am. J. Physiol. 288 (2005) H461-H468
29. Matsusaka H., Ide T., Matsushima S., Ikeuchi M., Kubota T., Sunagawa T., Kinugawa S., and Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47 (2006) 711-717
30. Medugorac I. Characterization of intramuscular collagen in mammalian left ventricle. Basic Res. Cardiol. 77 (1982) 589-598
31. Nagase H., and Okada Y. Proteinases and matrix degradation. In: Kelly W.N., Harris E.D., Ruddy S., and Sledge C.B. (Eds). Textbook of Rheumatology (1997), W.B. Saunders, New York 323-341
32. Peterson J.T., Li H., Dillon L., and Bryant J.W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc. Res. 46 (2000) 307-315
33. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens. Res. 19 (1996) 1-8
34. Sato A., Suzuki H., Murakami M., Nakazato Y., Iwaita Y., and Saruta T. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 23 (1994) 25-30
35. Shapiro S.D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10 (1998) 602-608
36. Shohet R.V., Kisanuki Y.Y., Zhao X.S., Siddiquee Z., and Franco F. Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2088-2093
37. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90 (2002) 520-530
38. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ. Res. 82 (1998) 482-495
39. Spinale F.G., Coker M.L., Bond B.R., and Zellner J.L. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res. 46 (2000) 225-238
40. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol. Rev. 79 (1999) 215-262
41. Toth M., Irina Chvyrkova I., Margarida Bernardo M., Sonia Hernandez-Barrantes S., and Fridman R. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem. Biophys. Res. Commun. 308 (2003) 386-395
42. Tsutamoto T., Wada A., Maeda K., Hisanaga T., Maeda Y., Fukai D., Ohnishi M., Sugimoto Y., and Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
43. Tyagi S.C., Kumar S.G., Banks J., and Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J. Mol. Cell. Cardiol. 27 (1995) 2177-2189
44. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
45. Weber K.T., Pick R., Silver M.A., Moe G.W., Janicki J.S., Zucker I.H., and Armstrong P.W. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 82 (1990) 1387-1401
46. Whitworth J.A. Studies on the mechanisms of glucocorticoid hypertension in humans. Blood Pressure 3 (1994) 24-32
47. Yao J., and Eghbali M. Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy. Response of cardiac fibroblasts to thyroid hormone in vitro. Circ. Res. 71 (1992) 831-839
48. Ziegelhöffer-Mihalovicová B., Briest W., Baba H.A., Babler B., and Zimmer H.G. The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine treated rat hearts. Mol. Cell. Biochem. 247 (2003) 61-68